Table 1.
Baseline characteristics of mild AD patients (n = 109)
| Screening/baseline demographics | Mean ± SD or median [IQR] | Association with neutrophil factor (standardized β) | p value |
|---|---|---|---|
| Age (years) | 74.8 ± 8.1 | 0.292 | 0.011 |
| Male | 58% | − 0.139 | 0.572 |
| Education (years) | 15.1 ± 3.2 | − 0.052 | 0.670 |
| ApoE ε4 allele (number) |
“0” = 31% “1” = 49% “2” = 20% |
− 0.194 | 0.125 |
| MMSE score | 23.6 ± 1.9 | − 0.118 | 0.351 |
| CDR | 0.74 ± 0.25 | − 0.022 | 0.871 |
| Brain parenchymal fraction | 0.62 ± 0.04 | − 0.064 | 0.644 |
| White matter hyperintensity volume (cm3) | 0.36 [0.12, 0.91] | − 0.071 | 0.598 |
| Hippocampal volume (cm3) | 5.72 ± 2.71 (n = 81) | − 0.209 | 0.195 |
| Anti-inflammatory medication use (NSAID and corticosteroids use) | 54% | 0.014 | 0.956 |
| Corticosteroid use | 5% | − 0.283 | 0.367 |
| NSAID (excluding ASA 81 mg) use | 25% | − 0.400 | 0.177 |
| ASA (81 mg) use | 35% | 0.364 | 0.141 |
| Acetylcholinesterase inhibitor use | 88% | − 0.390 | 0.390 |
| Memantine use | 45% | 0.489 | 0.029 |